Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04968834 · ClinicalTrials.gov registry record
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy
A clinical trial of Leukemia and Myelodysplastic Syndromes, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 300
- Enrollment target
- 8
- Study locations
NCT04968834: Recruiting study of Leukemia and Myelodysplastic Syndromes, sponsored by Dana-Farber Cancer Institute.
NCT04968834 is a study of Leukemia and Myelodysplastic Syndromes that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 300 participants, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (38% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04968834, a study of Leukemia and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 8
- Study locations
Study Summary
This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. Understanding the genetic factors of the disease can also help investigator understand why the disease of some people can respond to certain therapies differently than others. The genomic profiling will be performed using bone marrow and blood samples that either have already been obtained during a previous clinical procedure or will be obtained at the time of a scheduled clinical procedure. Studying the genetic information in the cells of these samples will provide information about the origin, progression, and treatment of leukemia and myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood samples will allow for additional research and genomic assessments to be performed in the future.
Primary Outcome
To perform genomic profiling of pediatric leukemia using clinical genomics platforms and return results to treating oncologist. This objective will be accomplished by enrolling patients and obtaining samples for sequencing and banking. The pathologist-interpreted genomic test results will be returned to the treating oncologist.
Conditions Studied
Interventions
- GENETIC Genomic profiling
Study Locations (8)
Massachusetts
- Boston Children's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Connecticut
- Connecticut Children's Medical Center - Hartford
Maine
- Maine Medical Center - Portland
New Hampshire
- Dartmouth-Hitchcock - Lebanon
New York
- Albany Medical Center - Albany
Rhode Island
- Lifespan Cancer Institute - Providence
Vermont
- University of Vermont Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2033-06 |
What NCT04968834 shows while recruiting
NCT04968834 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (38% lower).
The record links to 3 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Genomic profiling is the first listed.
NCT04968834 lists 8 locations in 7 states (Massachusetts, Connecticut, Maine).
Frequently Asked Questions
What is clinical trial NCT04968834 about?
NCT04968834 is a clinical study titled "Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy". This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and ...
What is the current status of trial NCT04968834?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2021-06-11. Estimated completion is 2033-06.
What conditions does trial NCT04968834 study?
This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndrome.
What interventions are being tested in trial NCT04968834?
The interventions under investigation include: Genomic profiling (GENETIC).
Who is sponsoring clinical trial NCT04968834?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04968834 being conducted?
This trial has 8 study locations across Connecticut, Maine, Massachusetts, New Hampshire, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04968834's enrollment target sits among peer trials
300 28th of 233 higher than 205 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI